MAP2K7 and non-small cell lung carcinoma: A recent study has demonstrated that a K-RasG12C inhibitor potentiates the anticancer effect of the MEK, mTOR, and insulin-like growth factor 1 receptor (IFG1R) inhibitors in NSCLC cells.